Overview

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.
Phase:
Phase 2
Details
Lead Sponsor:
Joshua Woolley, MD/PhD
Treatments:
N,N-Dimethyltryptamine
Psilocybin